Skip to main content

Client News

MagForce AG announces successful capital increase of the subsidiary MagForce USA, Inc.

31st December 2019

Vivoryon Therapeutics is Included in AScX Index

20th December 2019

Expedeon shareholders approve sale of proteomics & immunotherapy business and name change to 4basebio AG

19th December 2019

Xenikos announces first patient receives T-Guard® for steroid-refractory acute GVHD in pivotal U.S.-based Phase 3 trial

18th December 2019

Topas Therapeutics Announces First Patient Enrolled in Phase 1 Trial with TPM203 in Pemphigus Vulgaris

18th December 2019

Adocia announces its financial calendar for 2020

17th December 2019

Lindis Blood Care GmbH: Over 5 million euros for Lindis Blood Care – development of a new product for the removal of tumor cells from surgical blood

11th December 2019

SYNIMMUNE GmbH Reports Interim Results of First-in-Human Study of Fc-Optimized Antibody FLYSYN for the Treatment of Acute Myeloid Leukemia

10th December 2019

Motif Bio plc: Confirmation of timing of voluntary delisting from the NASDAQ Capital Market

10th December 2019

Xenikos presents promising new data from expanded access program (EAP) using T-Guard® to treat steroid-refractory acute GVHD at ASH Annual Meeting

9th December 2019